Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors
05 Diciembre 2024 - 3:05PM
Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”)
(NASDAQ: MRVI), a global provider of life science reagents and
services to researchers and biotech innovators, announced that Carl
Hull will retire from his position as Executive Chairman of the
Board and that the Board of Directors has unanimously elected R.
Andrew Eckert to succeed him as Chairman of the Board, effective
December 5, 2024.
Carl Hull founded Maravai in 2014 and served as Chief Executive
Officer, assuming the role of Executive Chairman in October
2022.
“Leading Maravai has been the single most rewarding experience
in my career. I am extremely proud of what we have accomplished
together over the past 10 years,” stated Carl Hull. “I extend my
sincere thanks to Trey Martin, our CEO, the rest of our leadership
team and to the dedicated employees across the world who
enthusiastically serve our customers and their communities every
day. I am excited about the company’s future prospects and am
confident that Maravai has the team, the talent, and the technology
to deliver on its long-term objectives.”
"On behalf of the entire Board, I thank Carl for his incredible
commitment to Maravai since he founded the Company in 2014.” said
Constantine (“Dean”) Mihas, Board member and Co-CEO of GTCR. “I
congratulate him for his distinguished career and deeply appreciate
his vision and unwavering service to building Maravai and
positioning the company for long-term success. He has been a model
of corporate leadership and integrity in our industry and beyond,
and we wish him well in his well-deserved retirement."
Mihas continued, “We also want to welcome Andy as our new Chair
and Board member. Andy is a healthcare industry veteran with
extensive experience as an executive officer of several healthcare
companies. He brings deep knowledge of operations, strategic
planning, product development and marketing to our Board and has
valuable corporate governance insight gained from having served as
Chief Executive Officer and Director of publicly held companies. We
look forward to leveraging his impressive executive experience to
help guide Maravai to achieve significant scale.”
“I'm honored to join the Board of Directors at Maravai, a
company dedicated to innovation to help our customers improve human
health,” said Eckert. “I look forward to contributing to the
success and transformative impact of this remarkable organization
while concurrently driving long-term shareholder value."
About R. Andrew Eckert
Mr. Eckert is a Senior Adviser to Permira, a global private
equity leader. Prior to Permira, he served as CEO of Zelis, a
healthcare payments and cost containment business. Before Zelis, he
served as CEO of wound care leader Kinetic Concepts, Inc. (KCI)
from 2017 until its sale to 3M in 2019. Prior to joining KCI, he
served as Chief Executive Officer of Valence Health, an emerging
leader in value-based healthcare, until its sale in 2016. Andy
previously served as Chief Executive Officer of TriZetto, a leader
in payer information technology (acquired by Cognizant), and as
Chairman and Chief Executive Officer of CRC Health Group, a leading
behavioral health treatment provider (acquired by Acadia). Earlier
in his career, he was Chief Executive Officer of Eclipsys
Corporation from 2005 to 2009, and Chief Executive Officer of
SumTotal Systems from 2002 to 2005. Andy began his career at ADAC
Laboratories, including four years as Chairman and Chief Executive
Officer until its sale to Philips Medical Systems in 2000. Andy has
served on several corporate boards and is currently the Chairman of
Kipu Health, Lead Director at Fortrea (NASDAQ: FTRE), and a
Director at Becton, Dickinson and Company (NYSE: BDX). He was
Chairman of Varian Medical Systems for seven years until its
acquisition by Siemens Healthineers in 2021. He has a Bachelor of
Science in Industrial Engineering and a Master of Business
Administration, both from Stanford University.
About Maravai Maravai is a leading life
sciences company providing critical products to enable the
development of drug therapies, diagnostics, and novel vaccines and
to support research on human diseases. Maravai’s companies are
leaders in providing products and services in the fields of nucleic
acid synthesis and biologics safety testing to many of the world's
leading biopharmaceutical, vaccine, diagnostics and cell and gene
therapies companies.
Forward-looking Statements This press release
may contain "forward-looking statements" within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Investors are cautioned that statements in this
press release which are not strictly historical statements
constitute forward-looking statements, including, without
limitation, statements related to the expectation that Mr. Eckert
will help Maravai achieve scale and drive long-term shareholder
value, constitute forward-looking statements identified by words
like “plan,” “will,” “expect,” “may,” “anticipate,” or “could” and
similar expressions. Such forward-looking statements are subject to
a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, without
limitation, the risks and uncertainties described in greater detail
in the “Risk Factors” section of our most recent Annual Report on
Form 10-K and other filings with the U.S. Securities and Exchange
Commission. Actual results may differ materially from those
contemplated by these forward-looking statements, and therefore you
should not rely upon them. These forward-looking statements reflect
our current views and we do not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date hereof except as
required by law.
Contact Information:
Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Maravai LifeSciences (NASDAQ:MRVI)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Maravai LifeSciences (NASDAQ:MRVI)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024